Premium
Enhancement of tumor‐specific T‐cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma
Author(s) -
Mizukoshi Eishiro,
Nakamoto Yasunari,
Arai Kuniaki,
Yamashita Tatsuya,
Mukaida Naofumi,
Matsushima Kouji,
Matsui Osamu,
Kaneko Shuichi
Publication year - 2009
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.24882
Subject(s) - medicine , hepatocellular carcinoma , immune system , dendritic cell , immunotherapy , arterial embolization , antigen , tumor antigen , cytokine , tumor necrosis factor alpha , pathology , cancer research , immunology , embolization , surgery
Transcatheter arterial embolization (TAE) destroys a tumor by the induction of necrosis and/or apoptosis and causes inflammation with cytokine production, which may favor immune activation and presentation of tumor‐specific antigens. In the current study, we attempted to identify the effect of TAE on tumor‐specific T‐cell responses and the additional effect of dendritic cell (DC) infusion performed during TAE. The prevalence of tumor antigen‐specific T cells was determined by interferon‐γ enzyme‐linked immunospot analysis using alpha‐fetoprotein (AFP) and tumor antigen‐derived peptides in 20 and 13 patients with hepatocellular carcinoma (HCC) who received TAE and TAE with DC infusion, respectively. The increased frequency of AFP‐specific T cells was observed in 6 of 20 patients after TAE. It was observed more frequently in patients with DC infusion than in those with TAE alone. However, tumor recurrence was not completely prevented in patients albeit displayed enhanced immune responses. The evidence that the enhanced immune responses were transient and attenuated within 3 months was provided in time‐course analysis. In conclusion, TAE with DC infusion enhances the tumor‐specific immune responses more effectively than TAE alone. Although the effect is not sufficient to prevent HCC recurrence, these results may contribute to the development of novel immunotherapeutic approach for HCC.